NCT06721689 - PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2031

Conditions

Refractory Solid TumorsRelapsed Solid TumorsRelapsed NeuroblastomaRefractory NeuroblastomaRelapsed RhabdomyosarcomaRefractory Rhabdomyosarcoma

Interventions

DRUG

PEEL-224

PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor

DRUG

Vincristine

Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.

DRUG

Temozolomide (TMZ)

Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.

Trial Locations (1)

RECRUITING

Children's Hospital of Philadelphia, Philadelphia